NRG Oncology/GOG Studies
- Ovarian tumors are classified into three categories based on progenitor cell type: surface-epithelial, sex cord-stromal and germ cell neoplasms . Of these, epithelial ovarian cancers (EOCs which may, in fact, often originate from the fallopian tube) comprise the majority of cases, and these are usually diagnosed at an advanced stage with an associated poor prognosis. Serous epithelial ovarian carcinoma (SOC) is the most commonly observed subtype of EOC both in the United States  and worldwide [3,4].
- For the approximately 22,000 patients projected to be diagnosed with ovarian cancer in 2015, the vast majority will have epithelial ovarian cancer (EOC) . Maximal cytoreductive surgery and administration of adjuvant or neoadjuvant primary chemotherapy with a platinum and taxane combination regimen have proven to be the two most important factors influencing survival [2–6]. Apart from modifying the dose schedule  and route of administration of the platinum and taxane combination , there have been no new drugs alone or in combination with the platinum and taxane backbone that have resulted in improved overall survival (OS) .
- To determine the association between timing of adjuvant therapy initiation and survival of early stage ovarian cancer patients.
- We sought to validate the clinicopathologic implications and prognostic significance of ATR (ataxia telangiectasia mutated and Rad3-related) mutation in patients with endometrioid endometrial cancer and defective DNA mismatch repair enrolled in a cooperative group molecular staging study of endometrial cancer.